In patients, long‐acting GLP‐1R analogues such as liraglutide and semaglutide have been used for treatment of type 2 diabetes mellitus (T2DM), and obesity and are known to decrease cardiovascular disease and chronic kidney disease in people with T2DM.2, 3, 4, 5. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.